Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents.
about
Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disordersExendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's diseaseSystems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor SystemMouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.Altered cholesterol and fatty acid metabolism in Huntington diseaseBrief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 miceDelayed Onset and Reduced Cognitive Deficits through Pre-Conditioning with 3-Nitropropionic Acid is Dependent on Sex and CAG Repeat Length in the R6/2 Mouse Model of Huntington's Disease.Molecular characterization of skeletal muscle atrophy in the R6/2 mouse model of Huntington's diseaseA Metabolic Study of Huntington's Disease.Peroxisome Proliferator-Activated Receptor-gamma in Amyotrophic Lateral Sclerosis and Huntington's Disease.A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.Brain insulin dysregulation: implication for neurological and neuropsychiatric disorders.Activating transcription factor 6 derepression mediates neuroprotection in Huntington disease.Huntington's Disease and Diabetes: Chronological Sequence of its Association.XJB-5-131-mediated improvement in physiology and behaviour of the R6/2 mouse model of Huntington's disease is age- and sex- dependent.
P2860
Q24562763-3B640C0D-AB05-44D7-B11C-833738FBC877Q24647189-29190AA7-95FF-452A-BF47-98289048BEBDQ26999386-C91D5428-C857-46D8-9FEE-59B6F6F5A6CBQ27005950-7F2A5425-ADC6-4A3A-9F49-62AAF36B9D2BQ33517121-7404862F-6D64-432E-8BBF-410A3CACF581Q34080706-9658F558-464B-40ED-A257-24209A671346Q34459323-BB1341A9-192C-4E74-B02F-631693350384Q34520437-C3086E8B-F15B-4AFC-AF7E-9CC35CF5E0D0Q35086831-A50F80A9-B747-4BE4-AB9D-E9FAD13C99B6Q36445216-4A96E47B-D7AE-45DA-A938-98530C36FF5FQ37157528-58021268-74A1-49DF-BE60-46093D658971Q37345118-C823C6E5-CF76-4443-9115-A6C7266C1E79Q38075505-2C7B7DE0-CCC7-47C7-8B52-C6AE56F96D98Q42067930-7D396E1B-6CA5-4D83-BDA5-56851DD02579Q45811505-E0936D3F-872A-4DAE-AA3E-2625F601FDEAQ52328137-BE392AA3-18BE-42BA-A2F9-86D9FE86CD4E
P2860
Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Atypical diabetes associated w ...... ent with hypoglycaemic agents.
@en
Atypical diabetes associated w ...... ent with hypoglycaemic agents.
@nl
type
label
Atypical diabetes associated w ...... ent with hypoglycaemic agents.
@en
Atypical diabetes associated w ...... ent with hypoglycaemic agents.
@nl
prefLabel
Atypical diabetes associated w ...... ent with hypoglycaemic agents.
@en
Atypical diabetes associated w ...... ent with hypoglycaemic agents.
@nl
P2860
P1476
Atypical diabetes associated w ...... ment with hypoglycaemic agents
@en
P2860
P2888
P304
P356
10.1007/S00221-005-2357-Z
P577
2005-07-21T00:00:00Z
P6179
1012734873